Results 41 to 50 of about 41,587 (192)
Frontiers in Pharmacology, 2015 Several clinical trials have substantiated the efficacy of the co-administration of statins like atorvastatin and fibrates. Without information currently available about the interaction between the two drugs, a pharmacokinetic study was conducted to ...
Omar ePatiño-Rodríguez +9 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Purpose To quantify how often creatine kinase (CK) is measured after newly elevated aminotransferases in statin users, and whether absent CK data are associated with gastroenterology (GI) referrals. Methods Retrospective chart review of adult outpatients on statins with a first alanine/aspartate aminotransferase (ALT/AST) elevation during a 5 ...
Faris Shweikeh +5 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical ...
Katherine Z. Isoardi +3 more
wiley +1 more source
Efficacy of combined atorvastatin and argatroban therapy in acute cerebral infarction
Pakistan Journal of Pharmaceutical SciencesBackground: Acute cerebral infarction (ACI) is a disease which seriously affects the people's health. Objectives: To investigate the efficacy of combined atorvastatin and argatroban therapy in patients with ACI and its effects on cerebral hemodynamics ...
Weihua Xu +5 more
doaj +1 more source
BMC Complementary Medicine and Therapies, 2023 Background Cardiovascular disease and cancer are the main causes of morbidity and mortality worldwide. Studies have shown that these two diseases may have some common risk factors.
Yu-qian Li +10 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Dyslipidemia due to renal insufficiency is a common complication in patients with chronic kidney diseases (CKD), and a major risk factor for the development of cardiovascular events.
Zebin Jiang +13 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind +7 more
wiley +1 more source
Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients
British Journal of Clinical Pharmacology, EarlyView.Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen +14 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo +12 more
wiley +1 more source
Atorvastatin before percutaneous coronary intervention: A systematic review and meta-analysis.
PLoS ONEAtorvastatin is widely recommended for long-term secondary prevention in STEMI patients with no contraindication. Although high-dose atorvastatin has been shown to reduce important patient outcomes such as MACE, there is still doubt that high-dose ...
Mariano García-Campa +8 more
doaj +1 more source